TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12785418

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ability to speak English
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Availability of health insurance
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Knowledge of mammography
Number of subjects: 180
Study: 10752582

Group type: EXPERIMENTAL
Intervention: Modified Inverted Stick (MIS)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Visual Laser Beam Stick (LBS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Unassisted Walking (UW)
Number of subjects: 28
Study: 9411698

Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital block
Number of subjects: 51
Study: 1396725

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg t.i.d. followed by oral cefuroxime axetil 500 mg b.i.d.
Number of subjects: 512

Group type: COMPARATOR
Intervention: Amoxicillin plus clavulanic acid (1.2 g intravenously t.i.d. followed by 625 mg orally t.i.d.)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Cefuroxime/cefuroxime axetil
Number of subjects: 512

Group type: COMPARATOR
Intervention: Amoxicillin/CA
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Cefuroxime regimen
Number of subjects: 512
Study: 3091097

Group type: EXPERIMENTAL
Intervention: 300 mg/day methylene blue
Number of subjects: 31

Group type: COMPARATOR
Intervention: 15 mg/day methylene blue (control)
Number of subjects: 31
Study: 30532527

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 µg/day
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 27884204

Group type: EXPERIMENTAL
Intervention: TME + LLND
Number of subjects: 512

Group type: COMPARATOR
Intervention: TME
Number of subjects: 512
Study: 24277915

Group type: EXPERIMENTAL
Intervention: Silirum vaccine
Number of subjects: 3335

Group type: COMPARATOR
Intervention: Control (no vaccination)
Number of subjects: 3335
Study: 22176900

Group type: EXPERIMENTAL
Intervention: Yinzhihuang oral liquid combined with phototherapy
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Phenobarbital combined with phototherapy
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Phototherapy
Number of subjects: 1177
Study: 18831071

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (PASCET-PI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 41
Study: 17571600

Group type: EXPERIMENTAL
Intervention: Milrinone (M group) administered continuously at a rate of 0.15‐0.30 microg x kg(‐1) min(‐1) after sternotomy until the end of operation.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (C group) received saline.
Number of subjects: 30
Study: 15257113

Group type: EXPERIMENTAL
Intervention: GES ON
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GES OFF
Number of subjects: 9

Group type: COMPARATOR
Intervention: Medication NR
Number of subjects: 9

Group type: COMPARATOR
Intervention: Medication RES
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 9
Study: 11448916

Group type: EXPERIMENTAL
Intervention: Antiangiogenic therapy with razoxane
Number of subjects: 43
Study: 9699660

Group type: EXPERIMENTAL
Intervention: NAT rapid acetylation genotype
Number of subjects: 433

Group type: COMPARATOR
Intervention: NAT1 rapid acetylation genotype
Number of subjects: 433

Group type: COMPARATOR
Intervention: NAT2 rapid acetylation genotype
Number of subjects: 433

Group type: COMPARATOR
Intervention: NAT1/NAT2 combined rapid acetylation genotype
Number of subjects: 433
Study: 8064281

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with radiation therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Radiation therapy alone (Control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Overall survival (both groups)
Number of subjects: 86
Study: 2729484

Group type: EXPERIMENTAL
Intervention: Hot/Ice Thermal Blanket
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no Hot/Ice unit)
Number of subjects: 54
Study: 4951240

Group type: EXPERIMENTAL
Intervention: 0.2 mg fentanyl intramuscularly
Number of subjects: 75

Group type: COMPARATOR
Intervention: 10 mg morphine intramuscularly
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: fentanyl
Number of subjects: 75

Group type: COMPARATOR
Intervention: morphine
Number of subjects: 75
Study: 30489494

Group type: COMPARATOR
Intervention: Evening Training (ET)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morning Training (MT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 50
Study: 27171508

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily (monotherapy)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily (add-on to metformin)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily (add-on to pioglitazone)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Alogliptin (any treatment group)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Alogliptin and placebo
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 25511300

Group type: EXPERIMENTAL
Intervention: Commercial toothpaste (1100 ppm F, pH7.0 and conventional viscosity)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice (ELD) (1100 ppm F, pH7.0 and low viscosity)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ELD (1100 ppm F and high viscosity pH7.0)
Number of subjects: 19

Group type: COMPARATOR
Intervention: NaF solution at pH4.5
Number of subjects: 19

Group type: COMPARATOR
Intervention: NaF solution at pH7.0
Number of subjects: 19

Group type: COMPARATOR
Intervention: Toothbrushing
Number of subjects: 19
Study: 23586654

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1234
Study: 22069045

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2b plus lamivudine 100 mg/d
Number of subjects: 59

Group type: COMPARATOR
Intervention: PEG‐IFNα‐2b 1.5 µg/kg o. i. w.
Number of subjects: 59
Study: 19906442

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Psychodynamic psychotherapy
Number of subjects: 74
Study: 22151600

Group type: EXPERIMENTAL
Intervention: DASH diet adherence (top two quintiles)
Number of subjects: 34827
Study: 15795477

Group type: COMPARATOR
Intervention: Endurance training (45 min exercise at 70% VO2max, 4 times in the first week and 3 times in the next 2 weeks)
Number of subjects: 12
Study: 12196081

Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg, once daily, starting 6 hours after surgery)
Number of subjects: 7344

Group type: COMPARATOR
Intervention: Enoxaparin (approved regimens)
Number of subjects: 7344

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 7344

Group type: COMPARATOR
Intervention: Fondaparinux and Enoxaparin
Number of subjects: 7344
Study: 9706946

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.25 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.15 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cisatracurium 0.15 mg/kg
Number of subjects: 60
Study: 7888933

Group type: EXPERIMENTAL
Intervention: Dietitian advice
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Practice nurse advice
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Diet leaflet
Number of subjects: 309

Group type: COMPARATOR
Intervention: All groups pooled
Number of subjects: 309
Study: 2404050

Group type: EXPERIMENTAL
Intervention: Reduction of sodium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase of potassium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease of energy intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 389838

Group type: EXPERIMENTAL
Intervention: Indomethacin (3 x 25 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined indomethacin + sodium-salicylate (3 x 25 mg/day and 3 x 250 mg/day)
Number of subjects: 0
Study: 30203300

Group type: EXPERIMENTAL
Intervention: Trauma film exposure
Number of subjects: 95

Group type: COMPARATOR
Intervention: Neutral film exposure
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Trauma film exposure in males
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Skin conductance response in males
Number of subjects: 95
Study: 27796072

Group type: EXPERIMENTAL
Intervention: CAD-/CAM-produced monolithic LS2-crowns bonded to prefabricated titanium abutments without any physical models (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CAD-/CAM-fabricated ZrO2-suprastructures and hand-layered ceramic veneering with milled master models (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Complete digital workflow for test
Number of subjects: 20

Group type: COMPARATOR
Intervention: Complete digital workflow for control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laboratory work time for test
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laboratory work time for control
Number of subjects: 20
Study: 25596420

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 24343683

Group type: EXPERIMENTAL
Intervention: Training group (TG) with a protocol consisting of 10 stages, including breathing exercises, resistance training, stretching, and walking.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG) with routine exercise program.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG)
Number of subjects: 22
Study: 19830413

Group type: EXPERIMENTAL
Intervention: Pummelo juice with 50 mg sildenafil
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water with 50 mg sildenafil
Number of subjects: 6
Study: 17991471

Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha at 1.5 microg/kg every 20 days plus iron orally (n=21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo plus iron orally (n=20)
Number of subjects: 41
Study: 16191447

Group type: EXPERIMENTAL
Intervention: Canary
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Plant
Number of subjects: 144

Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 144
Study: 14763193

Group type: EXPERIMENTAL
Intervention: 50 mg of quinacrine at each cornual angle (3 double insertions, a month apart)
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: 100 mg of quinacrine at each cornual angle (single double insertion)
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: 252 mg to 360 mg of quinacrine (2 insertions, a month apart, fundal placement)
Number of subjects: 1997
Study: 11030470

Group type: COMPARATOR
Intervention: Nateglinide 120 mg 3 times daily before meals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nateglinide 120 mg plus metformin 500 mg, both 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nateglinide 60 or 120 mg 3 times daily plus metformin 1 g twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nateglinide 120 mg 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination therapy with troglitazone 600 mg daily
Number of subjects: 0
Study: 8654613

Group type: EXPERIMENTAL
Intervention: Pelvic and periaortic peritoneal closure (group I, n = 50)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Peritoneum non-closure (group II, n = 52)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All patients after chemotherapy
Number of subjects: 102
Study: 1794820

Group type: EXPERIMENTAL
Intervention: Conjunctival application of 20 micrograms adrenaline in both eyes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Instillation of 100 micrograms adrenaline into the anterior chamber
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced salt solution (controls) in the anterior chamber
Number of subjects: 40

Group type: COMPARATOR
Intervention: No adrenaline (controls) for strabismus surgery
Number of subjects: 40
Study: 6212962

Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg + Ethanol 50 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg + Ethanol 50 g
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo + Ethanol 50 g
Number of subjects: 6
Study: 30106333

Group type: EXPERIMENTAL
Intervention: Teethmate AP paste (TMAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer (TMD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NaF (0.21% means 950 ppm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No desensitizer treatment
Number of subjects: 40
Study: 29724222

Group type: EXPERIMENTAL
Intervention: Emotional IPV only
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Physical and emotional IPV
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Emotional IPV
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Physical IPV
Number of subjects: 935
Study: 26499112

Group type: EXPERIMENTAL
Intervention: 1.8 ml of 0.5% hyperbaric bupivacaine at 5 °C (group I, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1.8 ml of 0.5% hyperbaric bupivacaine at 23 °C (group II, n = 50)
Number of subjects: 100
Study: 22092804

Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone mineral (DBBM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Synthetic hydroxyapatite in a collagen matrix (S-HA)
Number of subjects: 30
Study: 20581690

Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Trivalent inactivated vaccine (TIV)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Both LAIV and TIV
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 243
Study: 18398813

Group type: EXPERIMENTAL
Intervention: Ethanol (12.5% concentration)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: De-alcoholised red wine
Number of subjects: 49
Study: 16329604

Group type: EXPERIMENTAL
Intervention: Glycine chelated iron (II)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12437796

Group type: EXPERIMENTAL
Intervention: Global Assessment of Functioning (GAF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scale for the Assessment of Positive Symptoms (SAPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scale for the Assessment of Negative Symptoms (SANS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social Behaviour Schedule
Number of subjects: 0
Study: 12542209

Group type: EXPERIMENTAL
Intervention: Caroverine (120 mg/day for 4 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Zinc sulfate (400 mg/day for 4 weeks)
Number of subjects: 77
Study: 10196910

Group type: EXPERIMENTAL
Intervention: Extended formalized information by an anaesthetic nurse
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard pre- and postoperative information by a ward nurse
Number of subjects: 101
Study: 7899404

Group type: EXPERIMENTAL
Intervention: Captopril (1.5-2.0 mg/h i.v.)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2535284

Group type: EXPERIMENTAL
Intervention: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes in horizontal position
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes with 15 degrees head-up tilt
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes with 15 degrees head-down tilt
Number of subjects: 14
Study: 381094

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study: 31614214

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI) - 6 sessions delivered via telephone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education Only Control (EOC) - 6 sessions delivered via telephone
Number of subjects: 0
Study: 27995641

Group type: EXPERIMENTAL
Intervention: Harm intended by perpetrator and perceived as intended to harm by target (II condition)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Harm not intended by perpetrator but perceived as intended to harm by target (NI condition)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Harm intended by perpetrator but not perceived as intended to harm by target (IN condition)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Harm not intended by perpetrator and not perceived as intended to harm by target (NN condition)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Control condition (C condition) which did not state any actual or perceived harmful intention
Number of subjects: 656
Study: 25974971

Group type: EXPERIMENTAL
Intervention: WFG-LASIK
Number of subjects: 34

Group type: COMPARATOR
Intervention: WFO-LASIK
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: WFG-LASIK and WFO-LASIK
Number of subjects: 34
Study: 23063111

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training (90 min, twice a week for six months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 21958447

Group type: EXPERIMENTAL
Intervention: CATCH-IT (Internet-based intervention for depression)
Number of subjects: 0
Study: 19450991

Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional median total sternotomy
Number of subjects: 78
Study: 17178823

Group type: EXPERIMENTAL
Intervention: Increased participation goal setting (n = 101)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual practice goal setting (n = 100)
Number of subjects: 201
Study: 15124190

Group type: EXPERIMENTAL
Intervention: Sonographic assessment of clubfoot during treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sonographic assessment of clubfoot
Number of subjects: 42
Study: 11495260

Group type: EXPERIMENTAL
Intervention: Tuberculin reaction sizes of 5-9 mm
Number of subjects: 241

Group type: COMPARATOR
Intervention: Tuberculin reaction sizes of 0-4 mm
Number of subjects: 241
Study: 9209648

Group type: EXPERIMENTAL
Intervention: NPM/ALK fusion cDNA detected in RNA from whole lymph node tissue
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NPM/ALK fusion sequences amplified from single H-RS cells
Number of subjects: 16
Study: 7960025

Group type: EXPERIMENTAL
Intervention: Metoclopramide with felodipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Felodipine alone
Number of subjects: 12
Study: 3296728

Group type: EXPERIMENTAL
Intervention: Pirmenol (50 mg intravenous bolus followed by 2.5 mg/min infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine (75 mg intravenous bolus followed by 3 mg/min infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29955020

Group type: EXPERIMENTAL
Intervention: X-ray group (EBUS-GS with fluoroscopy)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-X-ray group (EBUS-GS without fluoroscopy)
Number of subjects: 31
Study: 26647072

Group type: EXPERIMENTAL
Intervention: Treatment guidance based on continuous glucose monitoring (CGM) data
Number of subjects: 34

Group type: COMPARATOR
Intervention: Advice based on blood glucose and glycosylated haemoglobin (HbA1c) levels (nonintervention group)
Number of subjects: 34
Study: 25241887

Group type: EXPERIMENTAL
Intervention: Polymer-free paclitaxel-eluting stent (PF-PES)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stent (PB-PES)
Number of subjects: 165
Study: 22552026

Group type: EXPERIMENTAL
Intervention: Dietary fat oxidation in Asians
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dietary fat oxidation in whites
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 24-h fat oxidation in Asians
Number of subjects: 34

Group type: COMPARATOR
Intervention: 24-h fat oxidation in whites
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Carbohydrate oxidation in Asians
Number of subjects: 34

Group type: COMPARATOR
Intervention: Carbohydrate oxidation in whites
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Protein oxidation in Asians
Number of subjects: 34

Group type: COMPARATOR
Intervention: Protein oxidation in whites
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Body fat percentage in Asians
Number of subjects: 34

Group type: COMPARATOR
Intervention: Body fat percentage in whites
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fat-free mass index in Asians
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fat-free mass index in whites
Number of subjects: 34
Study: 20973155

Group type: EXPERIMENTAL
Intervention: Oxycodone (OX) 20 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine (MO) 30 mg/d
Number of subjects: 60
Study: 18540331

Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules (T-long) administered in the morning
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules (T-long) administered in the evening
Number of subjects: 18

Group type: COMPARATOR
Intervention: 200 mg tramadol extended-release capsules (T-long) administered in the morning and evening
Number of subjects: 18
Study: 15787899

Group type: EXPERIMENTAL
Intervention: Standard care plus weekly telephone contact by a diabetes nurse educator (DNE) for 6 months.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard diabetes management (control group).
Number of subjects: 46
Study: 12736400

Group type: EXPERIMENTAL
Intervention: Daily iron-folate supplementation
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: Weekly iron-folate supplementation
Number of subjects: 2088

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 2088
Study: 11014412

Group type: EXPERIMENTAL
Intervention: IY-81149 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IY-81149 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: IY-81149 5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 60
Study: 8676802

Group type: EXPERIMENTAL
Intervention: High protein diet (HPD) 1.6 g/kg BW + Enalapril (ENAL) 10 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low protein diet (LPD) 0.8 g/kg BW
Number of subjects: 8